Moderna, Inc. (NASDAQ:MRNA) Shares Purchased by Swedbank AB

Swedbank AB raised its stake in Moderna, Inc. (NASDAQ:MRNA - Free Report) by 11.3% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 94,685 shares of the company's stock after buying an additional 9,586 shares during the period. Swedbank AB's holdings in Moderna were worth $3,937,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. MassMutual Private Wealth & Trust FSB boosted its holdings in Moderna by 58.2% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company's stock worth $44,000 after purchasing an additional 389 shares in the last quarter. Blue Trust Inc. grew its stake in shares of Moderna by 53.1% during the fourth quarter. Blue Trust Inc. now owns 1,119 shares of the company's stock valued at $47,000 after purchasing an additional 388 shares during the last quarter. Larson Financial Group LLC lifted its holdings in Moderna by 53.5% in the third quarter. Larson Financial Group LLC now owns 910 shares of the company's stock valued at $61,000 after buying an additional 317 shares during the period. Rakuten Securities Inc. boosted its position in shares of Moderna by 477.3% during the third quarter. Rakuten Securities Inc. now owns 941 shares of the company's stock worth $63,000 after purchasing an additional 778 shares in the last quarter. Finally, Brooklyn Investment Group bought a new stake in Moderna in the 3rd quarter valued at $80,000. Institutional investors own 75.33% of the company's stock.

Moderna Stock Performance

Shares of MRNA traded up $0.81 during mid-day trading on Wednesday, reaching $34.98. The company had a trading volume of 9,352,083 shares, compared to its average volume of 12,944,100. The stock has a market capitalization of $13.46 billion, a P/E ratio of -6.01 and a beta of 1.59. Moderna, Inc. has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a quick ratio of 4.20, a current ratio of 4.39 and a debt-to-equity ratio of 0.05. The stock has a 50 day moving average of $40.42 and a two-hundred day moving average of $59.05.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, beating analysts' consensus estimates of ($1.89) by $1.92. The business had revenue of $1.90 billion during the quarter, compared to analysts' expectations of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The business's revenue was up 3.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.39) earnings per share. On average, analysts expect that Moderna, Inc. will post -9.18 earnings per share for the current year.

Insider Buying and Selling

In other Moderna news, insider Shannon Thyme Klinger sold 1,418 shares of the firm's stock in a transaction on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the sale, the insider now directly owns 19,717 shares in the company, valued at $843,690.43. This trade represents a 6.71 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders sold 2,664 shares of company stock worth $115,210. Company insiders own 15.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on MRNA shares. Berenberg Bank upped their price target on shares of Moderna from $33.00 to $42.00 and gave the company a "hold" rating in a research note on Thursday, January 16th. The Goldman Sachs Group lowered shares of Moderna from a "buy" rating to a "neutral" rating and dropped their price objective for the company from $99.00 to $51.00 in a research note on Wednesday, January 29th. Needham & Company LLC restated a "hold" rating on shares of Moderna in a report on Friday, November 8th. Barclays reduced their target price on shares of Moderna from $125.00 to $111.00 and set an "overweight" rating for the company in a research note on Friday, November 8th. Finally, Evercore ISI dropped their target price on shares of Moderna from $60.00 to $50.00 and set an "in-line" rating for the company in a research report on Monday, January 27th. Four analysts have rated the stock with a sell rating, fourteen have issued a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $67.26.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.